Abstract:Introduction: G protein-coupled receptor (GPR) 40 is abundantly expressed in β cells. GPR40 and GPR120 are also expressed on the intestinal L cells and activating GPR40 and GPR120 can stimulate L cells to secret glucagon like peptide (GLP)-1. GW 9508 is a small-molecule agonist of GPR40 and GPR120. It dose dependently potentiates glucose-stimulated insulin secretion. In this study, we investigated whether GW9508 can directly stimulate β-cell replication in vitro and in vivo and improve islet graft function in diabetic mice. Methods: To determine β-cell proliferation in vitro, C57BL/6 mouse islets were cultured for 4 days, with and without GW9508. BrdU was added on day 3 for overnight. Insulin and BrdU immunofluorescence staining was performed on intact islets. Insulin+ and BrdU+ β cells were accounted using confocal microscope. To determine islet graft function, 100 C57BL/6 mouse islets were transplanted under the left kidney of each streptozotocin induced-diabetic C57BL/6 mouse. Recipient mice were orally treated with vehicle for GW9508 (containing dimethyl sulfoxide) or with GW9508 at 10 mg/kg/day, starting from the day of islet transplantation. All recipient mice were also intraperitoneally treated with BrdU at 100 mg/kg/day to label the replicated cells. Islet graft function was monitored by measuring blood glucose level. At 4 weeks, left nephrectomy was performed to remove the kidney bearing islet grafts to determine β-cell replication in islet grafts. Results: Insulin+ and BrdU+ β cells in each cultured islet were 13.6±1.2 cells with 0.1 μM GW9508; 18.3±1.5 cells with 1 μM GW9508; and 27.4±2.4 cells with 10 μM GW9508 (P< 0.01, vs. 10.5±0.6 cells in each untreated islet). At 2 week after islet transplantation, normoglycemia was achieved in 50% vehicle-treated mice achieved (n=10) and 100% GW9508-treated mice achieved normoglycemia (n=10). Although all recipient mice achieved normoglycemia at 4 weeks with or without treatment, normoglycemia was achieved in significantly fewer days in GW9508-treated mice. The vehicle-treated mice achieved normoglycemia in 14.4 ±2.9 days, while GW9508-treated mice only required 6.4±2.9 days (P< 0.01). The percentage of insulin+ and BrdU+ β cells in islet grafts were significantly higher in GW9508-treated mice than in vehicle-treated mice. The mean percentage of insulin+ and BrdU+ β cells in islet grafts was 23.6±6.4% in GW9508-treated mice and 6.7±3.4% in vehicle-treated mice (P< 0.01). At 30 minutes treatment, plasma GLP-1 was 9.3±2.6 pM/L in vehicle-treated mice and 14.7±4.7 pM/L in GW9508-treated mice (P< 0.05). Conclusion: Our data demonstrated that GW9508 can stimulate β-cell replication and improve islet graft function. Targeting GPR40 and/or GPR120 is a new therapeutic approach to stimulate β-cell replication and to improve islet graft function.

Light-Mediated Enhancement of Glucose-Stimulated Insulin Release of Optogenetically Engineered Human Pancreatic Beta-Cells

Ultrafast Glucose-Responsive, High Loading Capacity Erythrocyte to Self-Regulate the Release of Insulin

Ultrasound-Targeted Microbubble Destruction Mediates Gene Transfection for Beta-Cell Regeneration and Glucose Regulation.

Successful β cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1.

Successful Β Cells Islet Regeneration in Streptozotocin-Induced Diabetic Baboons Using Ultrasound-Targeted Microbubble Gene Therapy with Cyclind2/cdk4/glp1

Tether-free Optogenetic Control of Insulin Secretion Using an Upconversion Nanoparticle-Doped Hydrogel Platform.

Far-red light-activated human islet-like designer cells enable sustained fine-tuned secretion of insulin for glucose control

A Self-Powered Optogenetic System for Implantable Blood Glucose Control

A glucose-blue light AND gate-controlled chemi-optogenetic cell-implanted therapy for treating type-1 diabetes in mice

Glucose‐Operated Widget (GLOW) for Closed‐Loop Optogenetic Glycemic Control

Genetically Encoded Synthetic Beta Cells for Insulin Biosynthesis and Release under Hyperglycemic Conditions

Optogenetic therapeutic strategies for diabetes mellitus

Hydrophobicity Regulation of Energy Acceptors Confined in Mesoporous Silica Enabled Reversible Activation of Optogenetics for Closed-Loop Glycemic Control

Glucagon Potentiates Insulin Secretion Via Beta-Cell Gcgr At Physiological Concentrations Of Glucose

Glucagon Potentiates Insulin Secretion Via β-Cell GCGR at Physiological Concentrations of Glucose

Stimulating Beta Cell Replication and Improving Islet Graft Function by A Gpr40 and Gpr120 Dual Agonist

A chemical-genetic approach to study G protein regulation of β cell function in vivo

Antidiabetic Close Loop Based on Wearable DNA-Hydrogel Glucometer and Implantable Optogenetic Cells

A synthetic BRET-based optogenetic device for pulsatile transgene expression enabling glucose homeostasis in mice

Profiling Glucose-Stimulated and M3 Receptor-Activated Insulin Secretion Dynamics from Islets of Langerhans Using an Extended-Lifetime Fluorescence Dye

Synthetic Beta Cells for Fusion-Mediated Dynamic Insulin Secretion